Deciphera Pharmaceuticals (DCPH) Misses Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts DCPH Hot Sheet
Join SI Premium – FREE
Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q4 EPS of ($1.51), $0.18 worse than the analyst estimate of ($1.33). Revenue for the quarter came in at $24.2 million versus the consensus estimate of $23.29 million.
For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Icahn Enterprises L.P. (INGR) Tops Q3 EPS by 12c ; Offers Guidance
- Korsana Biosciences, Inc. (KRSA) Misses Q3 EPS by 227c
- Lamar Advertising (LAMR) Misses Q3 EPS by 6c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
